Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Strategies; Reimbursement

Set Alert for Pricing Strategies and Reimbursement

UK Prices Show Volatility Of Recent Launches

Double-digit rises and falls in the average prices of recently-launched generics recorded by market researcher WaveData demonstrated the volatile pricing dynamics of the UK market in December.

United Kingdom Pricing Strategies

Australian Experts To Weigh Paying For Trastuzumab Biosimilars

Mylan’s Ogivri and Merck Sharp & Dohme’s Ontruzant trastuzumab biosimilars of Roche’s Herceptin will be considered for reimbursement listing when Australia’s PBAC advisory body next meets in March.
Australia Biosimilars

US Court Denies Attempt To Silence Leaks In Pricing Litigation

A host of leading generics firms have been denied a requested order to prevent leaks and potentially harmful public allegations as part of multi-district litigation over generics pricing in the US.

United States Legal Issues

Coherus Confirms Udenyca Launch And Brings In Chief Medical Officer

The California-based biosimilars player has come good on its promise to introduce early in the new year its first biosimilar in the US and the second biosimilar of Amgen’s Neulasta blockbuster; at the same time, biotech veteran Darlene Horton has joined Coherus’ management team.

Launches Biosimilars

Leaks And Prejudice Must End In US Multi-State Pricing Case

A host of leading generics firms have banded together to call for an order to prevent leaks and potentially harmful public allegations, as they confront ongoing multi-district litigation over generics pricing in the US.

United States Pricing Strategies

UK Price Concessions Fail To Keep Pace With Treble-Digit Rises

As several generic presentations see treble-digit average price rises in the UK, the country’s health department has reacted with a raft of price concessions. However, these have not always matched the prices recorded by market researcher WaveData.

United Kingdom Pricing Strategies
See All